Logo

Xantos to Use OriGene cDNA Clones for High-Throughput Screening

Aug 16, 2004

NEW YORK, Aug. 16 (GenomeWeb News) - OriGene Technologies said that German drug discovery firm Xantos Biomedicine has acquired access to OriGene's TrueClone collection of non-redundant, full-length human cDNA clones. Xantos will use its high-throughput cellular screening technology, XantoScreen, along with the clone collection to identify and functionally validate novel targets, the company said.

 

Financial terms of the deal were not disclosed.

Breaking News
The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.